These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 33434185)

  • 21. Interplay between EZH2/β-catenin in stemness of cisplatin-resistant HNSCC and their role as therapeutic targets.
    Milan TM; Eskenazi APE; Oliveira LD; Silva GD; Bighetti-Trevisan RL; Freitas GP; Almeida LO
    Cell Signal; 2023 Sep; 109():110773. PubMed ID: 37331417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Supramolecular nanodrug targeting CDK4/6 overcomes BAG1 mediated cisplatin resistance in oral squamous cell carcinoma.
    Zhao B; Qin X; Fu R; Yang M; Hu X; Zhao S; Cui Y; Guo Q; Zhou W
    J Control Release; 2024 Apr; 368():623-636. PubMed ID: 38479445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
    Yang M; Luo Q; Chen X; Chen F
    J Nanobiotechnology; 2021 Aug; 19(1):259. PubMed ID: 34454534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. p22phox confers resistance to cisplatin, by blocking its entry into the nucleus.
    Hung CC; Chien CY; Chiang WF; Lin CS; Hour TC; Chen HR; Wang LF; Ko JY; Chang CH; Chen JY
    Oncotarget; 2015 Feb; 6(6):4110-25. PubMed ID: 25686830
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
    Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
    Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HOXA1 silencing inhibits cisplatin resistance of oral squamous cell carcinoma cells via IκB/NF-κB signaling pathway.
    Zhu R; Mao Y; Xu X; Li Y; Zheng J
    Anticancer Drugs; 2024 Jul; 35(6):492-500. PubMed ID: 38477942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of AKT phosphorylation by GSK3β and PTEN to control chemoresistance in breast cancer.
    Gao C; Yuan X; Jiang Z; Gan D; Ding L; Sun Y; Zhou J; Xu L; Liu Y; Wang G
    Breast Cancer Res Treat; 2019 Jul; 176(2):291-301. PubMed ID: 31006103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Antihelminthic Niclosamide Inhibits Cancer Stemness, Extracellular Matrix Remodeling, and Metastasis through Dysregulation of the Nuclear β-catenin/c-Myc axis in OSCC.
    Wang LH; Xu M; Fu LQ; Chen XY; Yang F
    Sci Rep; 2018 Aug; 8(1):12776. PubMed ID: 30143678
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TIMELESS confers cisplatin resistance in nasopharyngeal carcinoma by activating the Wnt/β-catenin signaling pathway and promoting the epithelial mesenchymal transition.
    Liu SL; Lin HX; Lin CY; Sun XQ; Ye LP; Qiu F; Wen W; Hua X; Wu XQ; Li J; Song LB; Guo L
    Cancer Lett; 2017 Aug; 402():117-130. PubMed ID: 28583847
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated Expression of Zinc Finger Protein 703 Promotes Cell Proliferation and Metastasis through PI3K/AKT/GSK-3β Signalling in Oral Squamous Cell Carcinoma.
    Wang H; Deng X; Zhang J; Ou Z; Mai J; Ding S; Huo S
    Cell Physiol Biochem; 2017; 44(3):920-934. PubMed ID: 29176314
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Receptor for advanced glycation end product blockade enhances the chemotherapeutic effect of cisplatin in tongue squamous cell carcinoma by reducing autophagy and modulating the Wnt pathway.
    Zhao Z; Wang H; Zhang L; Mei X; Hu J; Huang K
    Anticancer Drugs; 2017 Feb; 28(2):187-196. PubMed ID: 27831944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of long non-coding RNA HOTAIR inhibits cisplatin resistance of gastric cancer cells through inhibiting the PI3K/Akt and Wnt/β-catenin signaling pathways by up-regulating miR-34a.
    Cheng C; Qin Y; Zhi Q; Wang J; Qin C
    Int J Biol Macromol; 2018 Feb; 107(Pt B):2620-2629. PubMed ID: 29080815
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of chemoresistant factors by protein expression analysis with iTRAQ for head and neck carcinoma.
    Nishimura K; Tsuchiya Y; Okamoto H; Ijichi K; Gosho M; Fukayama M; Yoshikawa K; Ueda H; Bradford CR; Carey TE; Ogawa T
    Br J Cancer; 2014 Aug; 111(4):799-806. PubMed ID: 25032734
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.
    Chen R; Li D; Zheng M; Chen B; Wei T; Wang Y; Li M; Huang W; Tong Q; Wang Q; Zhu Y; Fang W; Guo L; Fang S
    J Cell Mol Med; 2020 Feb; 24(3):2123-2134. PubMed ID: 31957179
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Macrophage‑derived exosomes attenuate the susceptibility of oral squamous cell carcinoma cells to chemotherapeutic drugs through the AKT/GSK‑3β pathway.
    Tomita R; Sasabe E; Tomomura A; Yamamoto T
    Oncol Rep; 2020 Nov; 44(5):1905-1916. PubMed ID: 32901850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PER2 binding to PDK1 enhances the cisplatin sensitivity of oral squamous cell carcinoma through inhibition of the AKT/mTOR pathway.
    Zheng H; Yu W; Ren J; Tang H; Li H; Zhang Z; Yin S; Yang K
    Cell Signal; 2024 Oct; 122():111327. PubMed ID: 39079621
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of Stromal Fibroblast-Induced WNT7A Associated with Cancer Cell Migration Through the AKT/CLDN1 Signaling Axis in Oral Squamous Cell Carcinoma.
    Kayamori K; Katsube KI; Hirai H; Harada H; Ikeda T
    Lab Invest; 2023 Oct; 103(10):100228. PubMed ID: 37541622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overexpression of β-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma.
    Li L; Liu HC; Wang C; Liu X; Hu FC; Xie N; Lü L; Chen X; Huang HZ
    Biomed Res Int; 2016; 2016():5378567. PubMed ID: 27529071
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DKK3 Overexpression Increases the Malignant Properties of Head and Neck Squamous Cell Carcinoma Cells.
    Katase N; Nishimatsu SI; Yamauchi A; Yamamura M; Terada K; Itadani M; Okada N; Hassan NMM; Nagatsuka H; Ikeda T; Nohno T; Fujita S
    Oncol Res; 2018 Jan; 26(1):45-58. PubMed ID: 28470144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PDK1 Inhibitor BX795 Improves Cisplatin and Radio-Efficacy in Oral Squamous Cell Carcinoma by Downregulating the PDK1/CD47/Akt-Mediated Glycolysis Signaling Pathway.
    Pai S; Yadav VK; Kuo KT; Pikatan NW; Lin CS; Chien MH; Lee WH; Hsiao M; Chiu SC; Yeh CT; Tsai JT
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768921
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.